- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
Patent holdings for IPC class C07D 515/22
Total number of patents in this class: 166
10-year publication summary
|
3
|
4
|
4
|
8
|
9
|
14
|
14
|
23
|
17
|
12
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Pharmaceutica N.V. | 3394 |
22 |
| Pharma Mar, S.A. | 210 |
17 |
| Zeno Management, Inc. | 23 |
8 |
| Vertex Pharmaceuticals Incorporated | 1600 |
7 |
| AstraZeneca AB | 2892 |
6 |
| Genzyme Corporation | 1262 |
5 |
| NATCO Pharma Limited | 208 |
5 |
| The Regents of the University of Michigan | 4711 |
4 |
| Abbvie Inc. | 1800 |
4 |
| AbbVie Deutschland GmbH & Co. KG | 261 |
4 |
| Jiangsu Hengrui Medicine Co., Ltd. | 707 |
4 |
| Inflazome Limited | 85 |
4 |
| Ascentage Pharma (Suzhou) Co., Ltd. | 182 |
4 |
| Ascentage Pharma Group Corp Limited | 127 |
4 |
| F. Hoffmann-La Roche AG | 7947 |
3 |
| Hoffmann-La Roche Inc. | 3439 |
3 |
| Gilead Sciences, Inc. | 2032 |
3 |
| Polyphor AG | 87 |
3 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 641 |
3 |
| Sionna Therapeutics, Inc. | 15 |
3 |
| Other owners | 50 |